Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical endpoints including pruritus, Investigator skin scoring system and patient global assessment No safety concerns have been observed to date in either ongoing clinical… Read More..

-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third… Read More..

Third-Quarter Net Revenue of $3.7 Million, a 55% Increase Over 2022; Net Loss from Continuing Operations Narrows 85% to $0.2 Million; $1.1 Million in Positive Year-to-Date Net Cash Flows from Operating Activities SOUTH ORANGE, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading… Read More..